Abbott launches dorsal root ganglion neurostim system in Europe

Abbott (NYSE:ABT) said today that it launched its Proclaim dorsal root ganglion neurostimulation system in Europe for patients suffering from chronic neuropathic pain. The Abbott Park, Il.-based company’s system targets sensory nerves packed within the dorsal root ganglion to directly target the area of the body where pain occurs and provide stronger pain relief compared to traditional spinal cord stimulation therapy. “Many patients battling chronic neuropathic pain have not found adequate relief from other forms of treatment, which is why dorsal root ganglion stimulation has been such an important therapeutic advancement for pain specialists worldwide,” Dr. Harold Nijhuis, an anesthesiologist from the Netherlands, said in prepared remarks. “With the approval of the Proclaim DRG System, I am able to address chronic focal pain for my patients while offering them access to new, patient-centric benefits and features to improve their therapy experience.” Abbott claims it is the only company to offer a neurostim device designed for DRG therapy. Patients with chronic neuropathic pain can access the company’s Proclaim platform and an iPod touch mobile digital device patient controller that features wireless communication via Bluetooth. “Abbott continues to pursue innovative solutions for chronic pain because far too many patients with chronic intractable pain battle symptoms that are not adequately managed with current therapies,” Abbo...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Neuromodulation/Neurostimulation Pain Management Regulatory/Clearance Wall Street Beat Abbott Source Type: news